Alzheimer’s drug firm Alzamend Neuro tanks (NASDAQ:ALZN)

Alzamend Neuro (Nasdaq:ALZN) sank nearly 17% intraday Monday as the Alzheimer’s disease drug developer continues to give back much of last week’s 170% first-day post-IPO pop.